Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.62 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apocynin SCHEMBL109372 | 0.90 | HTT (0.73) | HTTSLC22A6SLC22A8MEN1RAB9A | |
| Apocynin SCHEMBL108512 | 0.90 | HTT (0.73) | HTTSLC22A6SLC22A8MEN1RAB9A | |
| Apocynin SCHEMBL28429584 | 0.90 | HTT (0.73) | HTTSLC22A6SLC22A8MEN1RAB9A | |
| Apocynin SCHEMBL109514 | 0.90 | MEN1 (0.75) | HTTSLC22A6SLC22A8MEN1RAB9A | |
| Apocynin SCHEMBL29364797 | 0.90 | MEN1 (0.75) | HTTSLC22A6SLC22A8MEN1RAB9A | |
| Apocynin SCHEMBL464770 | 0.90 | MEN1 (0.75) | HTTSLC22A6SLC22A8MEN1RAB9A | |
| Vanillic Acid SCHEMBL28312392 | 0.89 | HTT (0.83) | HTTSLC22A6SLC22A8MEN1RAB9A | |
| Apocynin SCHEMBL1859599 | 0.89 | SLC22A6 (0.64) | HTTSLC22A6SLC22A8MEN1RAB9A | |
| Apocynin SCHEMBL28537029 | 0.88 | HTT (0.71) | HTTSLC22A6SLC22A8MEN1RAB9A | |
| Apocynin SCHEMBL30937977 | 0.88 | MEN1 (0.72) | HTTSLC22A6SLC22A8MEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024115926-A1 | FORMULATION COMPRISING APOCYNIN AND PAEONOL | AKL RESEARCH & DEVELOPMENT LTD (GB) | 2024-06-06 | — | — | WO | disclosed |
| CN-116999417-A | Liquid preparation containing paeonol and apocynin | AKL研究发展有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20230330017-A1 | LIQUID FORMULATION COMPRISING PAEONOL AND APOCYNIN | AKL RES & DEVELOPMENT LTD (GB) | 2023-10-19 | — | — | US | disclosed |
| CN-111372572-B | Liquid preparation containing paeonol and apocynin | AKL研究发展有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-11701325-B2 | Liquid formulation comprising paeonol and apocynin | AKL RESEARCH & DEVELOPMENT LTD (GB) | 2023-07-18 | — | — | US | disclosed |
| EP-4019005-A1 | LIQUID FORMULATION COMPRISING PAEONOL AND APOCYNIN | AKL Research&Development Ltd (GB) | 2022-06-29 | — | — | EP | disclosed |
| US-20220089600-A1 | TGFß INHIBITOR AND PRODRUGS | FUNDACIÓ INSTITUT DE RECERCA BIOMÈDICA (IRB BARCELONA) (ES) | 2022-03-24 | — | — | US | disclosed |
| EP-3713546-B1 | LIQUID FORMULATION COMPRISING PAEONOL AND APOCYNIN | AKL RESEARCH&DEVELOPMENT LTD (GB) | 2021-12-08 | — | — | EP | disclosed |
| EP-3883556-A2 | TGF? INHIBITOR AND PRODRUGS | Fundació Institut de Recerca Biomèdica IRB (Barcelona) (ES) | 2021-09-29 | — | — | EP | disclosed |
| EP-3713546-A1 | LIQUID FORMULATION COMPRISING PAEONOL AND APOCYNIN | AKL Research&Development Ltd (GB) | 2020-09-30 | — | — | EP | disclosed |
| US-20200297628-A1 | LIQUID FORMULATION COMPRISING PAEONOL AND APOCYNIN | AKL RESEARCH & DEVELOPMENT LTD (GB) | 2020-09-24 | — | — | US | disclosed |
| CN-111372572-A | Liquid preparation containing paeonol and apocynin | AKL研究发展有限公司 | 2020-07-03 | — | — | CN | disclosed |
| WO-2019101842-A1 | LIQUID FORMULATION COMPRISING PAEONOL AND APOCYNIN | AKL RESEARCH & DEVELOPMENT LTD (GB) | 2019-05-31 | — | — | WO | disclosed |
| WO-2013037843-A1 | FORMULATION FOR THE TREATMENT OF BENIGN PROSTATE HYPERPLASIA | AKL INFLAMMATORY LIMITED (GB) | 2013-03-21 | — | — | WO | disclosed |
| EP-1868586-B1 | ANTI-INFLAMMATORY FORMULATION | AKL INFLAMMATORY LTD (GB) | 2012-11-21 | — | — | EP | disclosed |
| US-20090215886-A1 | Anti-Inflammatory Formulation | AKL RESEARCH AND DEVELOPMENT LIMITED (GB) | 2009-08-27 | — | — | US | disclosed |
| EP-1868586-A1 | ANTI-INFLAMMATORY FORMULATION | AKL Inflammatory Limited (GB) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006106350-A1 | ANTI-INFLAMMATORY FORMULATION | AKL INFLAMMATORY LIMITED (GB) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701325-B2 | Liquid formulation comprising paeonol and apocynin | LPL, PNLIP, LPO | HTT 1028/4885SLC22A6 1497/4885SLC22A8 2830/4885 |
| US-20220089600-A1 | TGFß INHIBITOR AND PRODRUGS | TGFB1, TGFBR1, TGFBR2 | HTT 4458/4885SLC22A6 809/4885SLC22A8 1079/4885 |
| US-20090215886-A1 | Anti-Inflammatory Formulation | IL1B, MPO, TNF | HTT 1164/4885SLC22A6 2502/4885SLC22A8 3974/4885 |
| US-20200297628-A1 | LIQUID FORMULATION COMPRISING PAEONOL AND APOCYNIN | LPL, PNLIP, LIPA | HTT 1366/4885SLC22A6 1080/4885SLC22A8 2269/4885 |
| US-20230330017-A1 | LIQUID FORMULATION COMPRISING PAEONOL AND APOCYNIN | LPL, PNLIP, LPO | HTT 1028/4885SLC22A6 1497/4885SLC22A8 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.